Pure Protein, L.L.C. is a biotechnology company focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.
Pure Protein is proud to announce the launch of its new website www.hlaprotein.com to offer researchers naturally folded and endogenously loaded soluble HLA proteins and improved vaccination and therapeutic targeting strategies through its HLA peptide epitope binding services to validate, screen, or map immune targets.
About Us
Founded in 1999, Pure Protein is a portfolio company of leading life sciences technology management firm Emergent Technologies, Inc. Pure Protein’s business operations are based in Austin, TX with research & development and production facilities in Oklahoma City, OK.
Pure Protein addresses the commercial and research need for supply of single specificity, glycosylated HLA proteins. The company was founded on the unique and proprietary technologies developed by Chief Scientists Dr. William Hildebrand at the University of Oklahoma Health Sciences Center.
Pure Protein addresses the commercial and research need for supply of single specificity, glycosylated HLA proteins. The company was founded on the unique and proprietary technologies developed by Chief Scientists Dr. William Hildebrand at the University of Oklahoma Health Sciences Center.
Technology
Pure Protein has pioneered an approach to produce soluble forms of HLA Class I and Class II proteins (sHLA). Only Pure Protein can make significant quantities of this highly purified and naturally processed product. These endogenously loaded, naturally glycosylated proteins can be used for critical research and in the development of diagnostics and therapeutics needed for a variety of immunotherapy applications.
Pure Protein’s sHLA proteins provide superior scale, yield, and purity over other products. The genetic compositions, production methods, and uses, including antibody removal, antibody detection, and target discovery are protected by a series of issued and pending patents. In addition to patents, Pure Protein has developed a comprehensive suite of proprietary know-how and expertise over its years of HLA research.
Pure Protein’s sHLA are naturally glycosylated and loaded with the full repertoire of endogenous peptide ligands, unlike HLA production using bacterial and insect systems. Because Pure Protein synthesizes HLA proteins in mammalian cells rather than insect or bacterial cells, Pure Protein’s sHLA circumvent the purification and production issues afflicting competing technologies. After over twenty years of research, Pure Protein has developed hundreds of Class I and Class II sHLA proteins representing all major classes A, B, C, DR, DQ, DP.
Pure Protein’s sHLA proteins provide superior scale, yield, and purity over other products. The genetic compositions, production methods, and uses, including antibody removal, antibody detection, and target discovery are protected by a series of issued and pending patents. In addition to patents, Pure Protein has developed a comprehensive suite of proprietary know-how and expertise over its years of HLA research.
Pure Protein’s sHLA are naturally glycosylated and loaded with the full repertoire of endogenous peptide ligands, unlike HLA production using bacterial and insect systems. Because Pure Protein synthesizes HLA proteins in mammalian cells rather than insect or bacterial cells, Pure Protein’s sHLA circumvent the purification and production issues afflicting competing technologies. After over twenty years of research, Pure Protein has developed hundreds of Class I and Class II sHLA proteins representing all major classes A, B, C, DR, DQ, DP.
Products and Applications
sHLA Proteins – Pure Protein has developed hundreds of Class I and Class II single specificity, glycosolated HLA proteins suitable for a wide variety of diagnostic and therapeutic applications. For parties interested in acquiring these proteins, please use the info contained in the “Contact Us” page.
Target Discovery Applications – Pure Protein’s sister company is Pure MHC, LLC. Pure MHC is a platform technology company with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious, autoimmune diseases and allergy. To learn more please visit the
Pure MHC website.
Pure MHC website.
Transplantation Therapeutics and Diagnostics – Pure Transplant Solutions, LLC. is a Pure Protein subsidiary, founded to develop the core HLA technologies into solutions that address a growing list of needs in organ transplantation. For more information please visit the
Pure Transplant Solutions website.
Pure Transplant Solutions website.
Collaborations - Pure Protein and its subsidiaries are collaboration driven. For partnership inquiries, please refer to the “Contact Us” page.
News
October 15, 2020 - Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting
March 20, 2020 - OU Health Sciences Center Partners With Pure MHC on COVID-19 Vaccine Project
February 13, 2019 - Emergent Technologies, Inc. Hires Steven Lloyd Mayer, MD as Chief Medical Officer and Promotes Blake Harlan to Executive Vice President Finance and Operations
January 9, 2017 - Pure MHC to Partner with AbbVie on Oncology Research
April 5, 2016 - GMS Biotech and Pure Protein Awarded Two Year $2,609,551 SBIR Grant to Develop sHLA Protein Chip for Anti-HLA Antibody Screening & Monitoring
February 1, 2016 - Pure Transplant Solutions Names Steven Lloyd Mayer, MD as Chief Medical Officer
March 20, 2020 - OU Health Sciences Center Partners With Pure MHC on COVID-19 Vaccine Project
February 13, 2019 - Emergent Technologies, Inc. Hires Steven Lloyd Mayer, MD as Chief Medical Officer and Promotes Blake Harlan to Executive Vice President Finance and Operations
January 9, 2017 - Pure MHC to Partner with AbbVie on Oncology Research
April 5, 2016 - GMS Biotech and Pure Protein Awarded Two Year $2,609,551 SBIR Grant to Develop sHLA Protein Chip for Anti-HLA Antibody Screening & Monitoring
February 1, 2016 - Pure Transplant Solutions Names Steven Lloyd Mayer, MD as Chief Medical Officer
Contact Us
Managed by Emergent Technologies, Inc.
Research Facilities
Pure Protein, LLC
655 Research Parkway, Suite 525
Oklahoma City, Oklahoma 73104
Phone: (405) 271-3838
Email: info@pureproteinllc.com
Pure Protein, LLC
655 Research Parkway, Suite 525
Oklahoma City, Oklahoma 73104
Phone: (405) 271-3838
Email: info@pureproteinllc.com
Business Operations
Emergent Technologies, Inc.
7500 Rialto Blvd., Building 2, Suite 260
Austin, Texas 78735
Phone: (512) 263-3232
Email: info@etibio.com
Emergent Technologies, Inc.
7500 Rialto Blvd., Building 2, Suite 260
Austin, Texas 78735
Phone: (512) 263-3232
Email: info@etibio.com